Bradway's patient dealmaking brings Onyx to Amgen

New YORK (Reuters) – Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc’s successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.

Powered by WPeMatico

This entry was posted in World News. Bookmark the permalink.

Comments are closed.